A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors
一项首次人体试验、开放标签、剂量递增和剂量扩展的 I 期研究，旨在评估人源化抗 PD-1 单克隆抗体 QL1604 在晚期或转移性实体瘤患者中的安全性、耐受性、药代动力学/药效学和抗肿瘤活性。
期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2023.1258573
Huang, Zhiyu; Xu, Yanjun; Hong, Wei; Gong, Lei; Chen, Kaiyan; Qin, Jing; Xie, Fajun; Wang, Feng; Tian, Xin; Meng, Xiangrui; Feng, Wenlei; Li, Lingyan; Zhang, Baihui; Kang, Xiaoyan; Fan, Yun
